QUOTE AND NEWS
New York Times  May 26  Comment 
The biotechnology company will sharply increase funding for the longtime high school contest with which Intel ended its relationship last year.
Motley Fool  May 17  Comment 
Both companies promise upside potential, but which one is the better choice for new money today?
Benzinga  May 14  Comment 
Featured stories this weekend in Barron's ponder the prospects for a leading biopharmaceutical company, a manufacturer of automotive paints and a little-known insurance holding company. This issue also offers thoughts on economic reform from an...
Forbes  May 12  Comment 
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in FedEx Corp (NYSE: FDX), where a total of 9,884 contracts have traded so far, representing approximately 988,400 underlying shares. That amounts...
Motley Fool  May 7  Comment 
The company top-selling eye disease drug continues to grow rapidly, but an increase in spending caused profits to wane.
Motley Fool  May 5  Comment 
First quarter earnings could impact trading in this big cap biotech. Here's what you need to know.
newratings.com  May 5  Comment 
WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) reported a profit for first quarter that decreased from last year. The company said its profit declined to $293 million, or $2.57 per share. This was down from $336 million, or $2.88 per...
newratings.com  May 5  Comment 




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki